1 The Trend of Ischemic Evaluation, Intervention, and In-Hospital Mortality

2 and Outcomes among Patients with Acute Myocardial Infarction and Atrial

3 Fibrillation

	4
	5
	6
	7
	8
	9
	10
	11
	12
	13
Mirza Faris Ali Baig, MI	14
Asante Physician Partne	15
baigfaris90@gmail.com	16
(630)-998-3986	17
2214 Haviland Drive, Grants Pass	18
Oregon, USA, 9752	19
Manuscript word count: 4899	20

It is made available under a CC-BY-NC-ND 4.0 International license .

21 Abstract:

22 Background: Atrial fibrillation (AF) is associated with increased cardiovascular mortality. Data 23 regarding the relationship between coronary artery disease (CAD) and AF is mixed. It is 24 uncertain if AF directly increases the risk for future coronary events and if such patients are 25 appropriately evaluated for CAD. Methods: This is a cross-sectional study performed on hospitalized patients with AMI and 26 concurrent AF in 2019 using National Inpatient Sample from HCUP. Patients with missing 27 28 information and type II non-ST elevation myocardial infarction (NSTEMI) were excluded. Using 29 STATA 18, In-hospital mortality, ischemic evaluation, percutaneous treatment, rates of 30 ventricular tachycardiac (VT), ventricular fibrillation (VF), cardiogenic shock, cardiac arrest, average length of stay (LOS), and total hospitalization charges were studied. Regression models 31 32 were used for data analyses. Results: A total of 600,645 patients met inclusion criteria (219,660 females [36.5%], 428,755 33 Caucasian [71%], 65,870 African American [10.9%], 51,155 Hispanic [8.5%]; mean [SD] age, 34 66.7 [0.5] years), including 166,680 (28%) STEMI and 433,965 (72%) NSTEMI patients. 35 109,520 (18%) patients with AMI had AF. For patients with AMI and AF, the adjusted odds of 36 mortality increased by 23% (adjusted Odds ratio [aOR], 1.23; CI, 1.15-1.32; p<0.001). AF 37 patients were less likely to undergo ischemic evaluation (aOR, 0.77; CI, 0.74-0.80; p<0.001) and 38 39 ischemic intervention (aOR, 0.64; CI, 0.62-0.66; p<0.001). AF patients had higher odds of VT (aOR, 1.41; CI, 1.33-1.49; p<0.001), VF (aOR, 1.44; CI, 1.33-1.57; p<0.001), cardiogenic shock 40 (aOR, 1.43; CI, 1.35-1.52; p<0.001), and cardiac arrest (aOR, 1.35; CI, 1.24-1.47; p<0.001). AF 41 patients had longer LOS (mean, 1.39; SCD, 1.29-1.48; p<0.001) and higher total hospital charges 42 43 (mean \$22,188; 19,311-25,064, p<0.001).

44	Conclusion: AF was independently associated with increased mortality in patients admitted with
45	AMI. AF was associated with higher rates of cardiac complications. Patients with AF were less
46	likely to receive ischemic evaluation or percutaneous intervention and had overall higher
47	healthcare resource utilization. This study encourages AF to be viewed as an independent risk
48	factor for CAD and suggests more efforts to diagnose CAD in such patients.
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	

It is made available under a CC-BY-NC-ND 4.0 International license .

63 Clinical Perspective:

- 64 What is new:
- Patients with acute myocardial infarction and atrial fibrillation have higher odds of
 mortality.
- AMI patients with AF are subjected to lesser odds of undergoing ischemic evaluation and intervention.
- Healthcare resource utilization is higher in this cohort.
- 70 What are the clinical implications:
- AF should be considered as an independent risk factor for increased mortality in AMI.
- Early ischemic evaluation should be considered to diagnose coronary artery disease in
 this cohort.
- Increased awareness to recognize all risk factors of coronary artery disease.
- 75
- 76
- 77

- 78
- 79
- 80
- 81
- -
- 82

It is made available under a CC-BY-NC-ND 4.0 International license .

83 Non-standard abbreviations and acronyms:

- 84 AMI: Acute myocardial infarction
- 85 AF: Atrial fibrillation
- 86 STEMI: ST-elevation myocardial infarction
- 87 NSTEMI: Non-ST elevation myocardial infarction
- 88 VT: Ventricular tachycardia
- 89 VF: Ventricular fibrillation
- 90 LOS: length of stay
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99

It is made available under a CC-BY-NC-ND 4.0 International license .

101 Introduction:

Atrial fibrillation (AF) is the most common cardiac arrhythmia globally.¹ The prevalence of AF 102 in the US is at least 3-6 million and is projected to increase to 6-16 million by $2050.^2$ The 103 lifetime risk of acquiring AF is estimated to be 33%.³ AF is known to increase mortality from 104 sudden cardiac death, congestive heart failure, and stroke; $\frac{4}{2}$ therefore, it is not surprising that 105 healthcare costs associated with AF are significantly higher.⁵ Coronary artery disease (CAD), on 106 the other hand, is the most common cardiovascular disease.⁶ It is the leading cause of mortality 107 in the US, with approximately 610,000 deaths annually,⁷ and the third leading cause of death 108 worldwide, with 17.8 million deaths annually. $\frac{8.9}{100}$ Healthcare costs related to CAD are estimated 109 to be more than US\$200 billion annually.¹⁰ Due to the colossal healthcare burden, considerable 110 efforts have been made to understand the underlying risk factors. These risk factors are 111 segregated into two large categories: modifiable and non-modifiable risk factors. The non-112 modifiable risk factors include age, gender, family history, and certain ethnicities. The known 113 modifiable risk factors include hypertension, diabetes mellitus, hyperlipidemia, obesity, 114 smoking, sedentary lifestyle, and stress.¹¹ Significant efforts are made to discover novel risk 115 factors, aiming to formulate additional guidelines to alleviate substantial healthcare costs and 116 117 mortality rates.

118 While both diseases are known to share a common risk factor profile, the intricate relationship 119 between the two is still largely unclear. It is reported that CAD is a risk factor for AF;¹² however, 120 studies have shown mixed results about AF being an independent risk modifier for CAD, with 121 some proposing direct causality,¹³ whereas others suggesting no causal relationship between AF 122 and risk of CAD.¹⁴ It is not uncommon in practice for patients to have both AF and CAD. AF is 123 known to have a negative prognostic impact on CAD patients;¹⁵ yet, it remains unclear if the medRxiv preprint doi: https://doi.org/10.1101/2023.12.15.23300053; this version posted December 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

increased mortality is due to increased coronary ischemic events or from unfavorable
 hemodynamic effects, such as loss of atrial kick, high ventricular rate, and decreased cardiac
 output.¹⁶

Several studies have attempted to understand the impact of both diseases. While previous studies have explored the associated poor outcomes, no study has directly examined the pattern of diagnostic workup, intervention, and cardiac outcomes in this sub-population. This study aims to investigate the effect of AF on acute myocardial infarction (AMI) in terms of in-hospital mortality, serious cardiac complications, and hospital resource utilization and explore the national trend of ischemic evaluation and treatment in patients with both AMI and AF.

133 Methods:

134 This is a retrospective cohort study of adult patients hospitalized in the United States with the diagnosis of AMI. The study used the patient cohort from the National Inpatient Sample (NIS) 135 database from January 1, 2019 to December 31, 2019. The NIS is a part of the Healthcare Cost 136 and Utilization Project (HCUP), maintained by the Agency for Healthcare Research and Quality 137 (AHRO).¹⁷ NIS is sampled from the State Inpatient Databases (SID), containing information on 138 139 all hospital stays regardless of the payer source. NIS 2019 sampling frame included data from 49 statewide organizations, estimated to have 97% of discharges from non-federal short-term US 140 hospitals, covering 98% of the US population. NIS collects 20% of the stratified sample of 141 142 discharge records from all HCUP-participating US community hospitals, excluding long-term acute care facilities and rehabilitation centers. Discharge weights are provided to produce 143 national estimates, approximating 35 million discharges when weights are applied. This allows 144 NIS to provide reliable information about cardiovascular diseases. 145

146 Study patients:

It is made available under a CC-BY-NC-ND 4.0 International license .

Patients who were adults (≥18) and admitted non-electively were included. The ICD-10 CM
codes were used to identify patients hospitalized for ST-elevation myocardial infarction
(STEMI) and non-ST elevation myocardial infarction (NSTEMI). These patients were then
accumulated under the diagnosis of AMI for data analysis. The ICD-10 codes used are listed in
the attached Appendix. Patients with the diagnosis of NSTEMI type II or acute myocardial injury
due to secondary causes or a procedural complication were excluded. Patients with missing
information were also excluded from the analysis.

154 Study variables:

155 ICD-10 procedure codes were used to identify patients who underwent diagnostic evaluation for coronary artery disease. Diagnostic cardiac angiograms and non-invasive cardiac stress tests 156 were identified using the ICD-10 procedure codes and gathered under a single variable. 157 Percutaneous coronary intervention (PCI) procedure codes were used to identify patients who 158 159 underwent any percutaneous intervention (see Appendix). Secondary diagnosis codes were used to identify AF patients. Separate variables were created for all other comorbid conditions. Length 160 of stay (LOS) and total hospitalization charges are provided within the NIS data for each hospital 161 admission. Covariates included in the study were age, gender, race, baseline comorbidity status 162 163 using the Charlson Comorbidity Index, median annual income in the patient's zip code, geographic region of the United States (Northeast, Midwest, West or South), hospital location 164 165 (urban vs rural), hospital teaching status, hospital bed size, primary insurance, hypertension, 166 diabetes mellitus, hyperlipidemia, smoking status, obesity, history of coronary artery disease, history of myocardial infarction, history of percutaneous coronary intervention, systolic heart 167 168 failure, diastolic heart failure, combined systolic and diastolic heart failure, history of peripheral 169 vascular disease, chronic pulmonary disease, pulmonary hypertension, obstructive sleep apnea,

It is made available under a CC-BY-NC-ND 4.0 International license .

- acute kidney injury, chronic kidney disease, chronic liver disease, sepsis, septic shock, alcohol
- 171 use, cocaine, amphetamine use and anemia of chronic disease.
- 172 **Outcomes:**
- 173 The primary outcome was in-hospital mortality. Secondary outcomes were ischemic evaluation,
- 174 percutaneous ischemic intervention, rates of ventricular tachycardia (VT), ventricular fibrillation
- 175 (VF), cardiogenic shock, cardiac arrest, length of stay (LOS), and total hospitalization charges.
- 176 NIS provides in-hospital mortality, LOS, and total hospital charges. Separate variables were
- 177 created for other secondary outcomes.

178 Statistical Analysis:

STATA 18.0 was used to analyze the results. NIS is generated using a complex sampling design,
including stratification, clustering, and weighting. STATA can run analyses to provide nationally

181 representative unbiased results and generate p values.

182 Univariable and multivariable linear regression analyses were used to calculate means for

183 continuous variables. Univariable logistic regression analysis was used to calculate unadjusted

184 odds ratios (ORs) for categorical and dichotomous variables. A separate univariable logistic

regression analysis was performed to isolate statistically significant variables with a p-value of

less than 0.02. Those variables were then included in the multivariate logistic regression analysis

to adjust for potential confounders. Another analysis was conducted incorporating variables with

p-values between 0.02 and 0.05, along with those above 0.05 but known to be confounders in

189 previous studies, to validate our findings.

190 Fisher exact test was used to compare proportions. Student t-test was used for continuous

variables. All p-values obtained were two-sided. 0.05 was used as the threshold for statistical

192 significance.

It is made available under a CC-BY-NC-ND 4.0 International license .

193 **Results:**

194 **Patient characteristics:**

- A total of 35 million weighted discharges were included in the NIS 2019, of which 600,645 met
- the inclusion criteria of our study. 36% of the patients were females, and the predominant race
- 197 was Caucasian (73%). 166,680 (28%) patients had a primary diagnosis of ST-elevation
- 198 myocardial infarction (STEMI) and 433,965 (72%) with non-ST elevation myocardial infarction
- 199 (NSTEMI). 109,520 (18%) patients had a secondary diagnosis of AF. Patients with the
- secondary diagnosis of AF were more likely to be older, Caucasian, and insured by Medicare
- 201 compared to the patients without AF. Table 1 summarizes the baseline characteristics. The
- distribution of the female gender, Charlson comorbidity score, and other hospital-level
- 203 parameters such as the US geographic region, hospital location, and hospital bed size were
- similar in both groups. Although these differences were statistically significant, the absolute
- 205 differences were small.

206 **In-hospital mortality:**

The overall in-hospital mortality rate for AMI was 4.5%. The difference in mortality between patients with and without AF is presented in Table 2. AF independently predicted increased odds of mortality (adjusted OR, 1.23; CI, 1.15-1.32; p<0.001) on univariable and multivariable analyses that adjusted for patient- and hospital-level confounders. In-hospital mortality rates for STEMI and NSTEMI were 7.8% and 3.2%, respectively. Similar associations were found for STEMI (adjusted OR, 1.23; CI, 1.09-1.38; p<0.001) and NSTEMI (adjusted OR, 1.32; CI, 1.21-1.45; p<0.001), as summarized in Table 3.

214 In-hospital ischemic evaluation:

It is made available under a CC-BY-NC-ND 4.0 International license .

215	For patients admitted with AMI, the rate of in-hospital ischemic evaluation was 76%. Regarding
216	in-hospital ischemic evaluation, AF patients were less likely to undergo ischemic evaluation with
217	a diagnostic coronary angiogram or cardiac stress test after adjusting for confounders (adjusted
218	OR, 0.77; CI, 0.74-0.80; p<0.001).
219	Ischemic evaluation was performed in 90% and 71% of patients with STEMI and NSTEMI
220	admissions. As seen with AMI, patients with AF were less likely to undergo an ischemic
221	evaluation than those without AF for STEMI (adjusted OR, 0.78; CI, 0.70-0.86; p<0.001) and
222	NSTEMI (adjusted OR, 0.79; CI, 0.75-0.82; p<0.001). Like the primary outcome of mortality,
223	we obtained similar results after including all the variables with $p > 0.02$ but less than 0.05.
224	In-hospital ischemic intervention:
225	Among the patients admitted with AMI, 51.4% underwent PCI. 37.1% of patients with AF and
226	AMI had PCI compared to 54.6% without AF. After univariable screening and multivariable
227	logistic regression to neutralize potential confounders, AF patients were less likely to undergo
228	PCI than patients without AF (adjusted OR, 0.64; CI, 0.62-0.67; p<0.001), detailed in Table 4.
229	In a separate analysis, PCI was performed on 81.2% of all STEMI patients overall, though rates
230	were lower for patients with AF (70%) than those without AF (83.1%). After adjusting for
231	confounders, AF was an independent predictor of decreased odds of in-patient PCI (Adjusted
232	OR, 0.65; CI, 0.59-0.70; p<0.001). 40% of patients admitted with NSTEMI underwent PCI.
233	Patients diagnosed with AF had lower rates of PCI (28.2%) compared to patients without AF
234	(43%). AF was again an independent predictor for lesser odds of in-patient ischemic intervention
235	(Adjusted OR, 0.62; CI, 0.59-0.64; p<0.001).
236	Other important in-hospital cardiac outcomes:

- 237 The study assessed the occurrence rates of in-hospital serious cardiac complications such as
- ventricular tachycardia (VT), ventricular fibrillation (VF), cardiogenic shock, and cardiac arrest.
- The rates of VT were 7.3%, 13.5%, and 4.9% for AMI, STEMI, and NSTEMI, respectively.
- Notably, these rates were elevated in individuals with AF, with 9.5% vs. 6.8% for AMI, 18.3%
- 241 vs. 12.7% for STEMI, and 7.2% vs. 4.4% for NSTEMI.
- 242 Similarly, VF rates were 3.4% in AMI, 8.7% in STEMI, and 1.3% in NSTEMI. Again, AF was
- associated with higher rates (4.2% vs. 3.2% for AMI, 12.3% vs. 8.2% for STEMI, and 1.98% vs.
- 1.1% for NSTEMI). Incidences of cardiogenic shock were 6.7%, 14.1%, and 3.9% for AMI,
- STEMI, and NSTEMI, respectively. AF patients demonstrated elevated rates across all three
- 246 groups (10.4% vs. 5.9% in AMI, 24.7% vs. 12.4% in STEMI, and 6.5% vs. 3.3% in NSTEMI).
- 247 The rates of cardiac arrest were 2.9% in AMI, 5.9% in STEMI, and 1.7% in NSTEMI. Upon
- separate analysis based on AF status, higher cardiac arrest rates were observed in AF patients
- 249 (4% vs. 2.7% in AMI, 9.1% vs. 5.4% in STEMI, and 2.6% vs. 1.5% in NSTEMI patients).
- 250 As summarized in
- Table *5*, AF independently predicted increased odds of VT, VF, cardiogenic shock, and cardiac
 arrest.
- 253 Hospital length of stay and total hospitalization charges:
- 254 Patients with AMI had a mean length of stay of 4.36 days, with associated hospitalization
- charges of \$108,409; STEMI patients stayed 3.9 days, incurring charges of \$126,896, while
- NSTEMI patients had a mean stay of 4.5 days with charges totaling \$101,301. Following
- adjustments for patient- and hospital-level variables, individuals with AF exhibited significantly
- prolonged hospital stays and higher hospitalization charges compared to those without atrial
- 259 fibrillation, as summarized in Table 6 below:

It is made available under a CC-BY-NC-ND 4.0 International license .

260 Discussion:

This study demonstrates that patients with AMI and concomitant AF had poorer outcomes than those without AF. This subpopulation was not only found to have increased mortality, but they were also less likely to undergo ischemic evaluation and treatment, with higher rates of cardiac

- 264 complications, increased length of stay, and higher total hospitalization charges.
- 265 The interaction and causality relationship between CAD and AF is complex, and a large number of studies in the past have shown varied results. The prevalence of CAD in AF was previously 266 estimated to be between 18-46.5%, whereas the prevalence of AF in CAD was low, from 0.5 to 267 5%.^{12,18} In this study, the prevalence of CAD in AF was 40%, and the prevalence of AF in CAD 268 was 29%. One plausible explanation for such divergence is that most previous studies captured 269 longitudinal data and had fewer patients than this study. Previous research identified CAD as an 270 independent risk factor for the development of AF,¹⁹ and early onset AF post-AMI is linked with 271 a dismal prognosis.²⁰ Studies have demonstrated poor short and long-term outcomes in patients 272 with AMI and AF.²¹ The large Global Registry of Acute Coronary Events (GRACE) showed a 273 three-fold increased risk of death for patients with new-onset AF during index hospitalization for 274 acute coronary syndrome.²² This study concurs with previous findings and found AF as an 275 276 independent predictor for increased odds of mortality while controlling for other known variables associated with increased mortality. 277

Several mechanisms are considered the possible etiology behind increased mortality in this subpopulation. One theory suggested that due to shared risk factors between the two conditions, AF and CAD are both the products of these underlying risk factors that promote atrial ischemia, induce AF, and encourage obstructive coronary artery disease.²³ Another hypothesis suggests reentry pathways with different refractory times create reentry circuits and, along with the

283	structural remodeling of the left atriun	n, increase vulnerability	y to AF. $\frac{24,25}{25}$ Very few cases of

- thromboembolic AMI have been reported with AF due to the associated systemic inflammatory
- state promoting prothrombotic environment. $\frac{26,27}{2}$ Lastly, the increased ventricular rate can induce
- subendocardial ischemic and cause NSTEMI.²⁸
- 287 One study found no association between a history of AF and significant CAD in patients
- undergoing coronary angiograms.²⁹ In contrast, another research revealed that the vast majority
- of deaths in anticoagulated AF patients were from cardiac causes (37%) rather than stroke
- (9.8%).³⁰ Adding complexity, a prospective cohort study demonstrated an association between
- AF and NSTEMI and not with STEMI.³¹ Despite AF showing an increased mortality in AMI,²⁰ it
- remains uncertain whether increased coronary events are the primary cause.
- 293 Pooled data from a 2016 meta-analysis showed a 39% elevated risk of AMI in AF patients and a
- two-fold increased likelihood of cardiovascular events or death compared to patients without
- $AF.^{32}$ In another longitudinal study, AF was associated with a two-fold increased risk for MI, and
- the risk of mortality was notably higher in an African American female on anticoagulation with a
- high ChadsVasc score. $\frac{13}{13}$ However, our study found no statistically significant difference in
- 298 mortality between genders (adjusted OR 1.02, p 0.498).
- 299 Single-center retrospective analysis showed no association between anatomical characteristics of
- 300 CAD and AF; however, it found more severe CAD in patients with AF.³³ Given the high
- 301 mortality linked with AF and AMI and previous studies indicating a higher likelihood of severe
- 302 CAD in this patient population, data was analyzed in this study to assess the trend of ischemic
- 303 evaluation and intervention in patients admitted with AMI and stratified them based on AF
- 304 status. The study showed increased mortality and decreased odds of undergoing ischemic

It is made available under a CC-BY-NC-ND 4.0 International license .

evaluation with a nuclear stress test or diagnostic coronary angiogram. The study also showed
lesser odds of receiving percutaneous interventions.

307 Similarly, patients with AF were more likely to have serious cardiovascular complications such

308 as VT, VF, cardiogenic shock, and cardiac arrest compared to patients without AF. The average

length of hospital stays and total hospital charges were also high in AF. This study validates the

310 previous findings of increased mortality in patients with CAD and concomitant AF. It further

311 highlights the deficits in diagnostic evaluation in this patient population, which was not

examined before. The study indicated an increased propensity for cardiac complications and

elevated resource utilization, underscoring the crucial importance of treating AF as a distinct risk

factor for CAD and advocating for early ischemic evaluation.

Limitations: Our study had the following limitations. It included all-cause mortality as the

outcome instead of cardiovascular-specific mortality, as CV mortality is not available in the

dataset. There is a potential for coding error as the ICD-10 codes' accuracy depends on the

treating physician. The patients with missing information were excluded from the analysis,

319 which may infer selection bias. The anticoagulation status of AF patients was not known.

320 Conclusion:

321 This study examined the impact of AF on CAD mortality, cardiac complications, length of stay,

and total hospital charges. AMI patients with AF had higher odds of mortality. They were less

323 likely to undergo ischemic workup or intervention, more likely to suffer serious cardiac

324 complications, and, on average, had longer lengths of hospital stay and higher hospital charges.

- 325 AF appears to affect cardiovascular mortality independently. AF should be considered as a
- marker for underlying CAD. More research is required to understand the challenges of obtaining

It is made available under a CC-BY-NC-ND 4.0 International license .

327 ischemic workup in AF patients. More education is needed to promote early conside	eration of
---	------------

328 ischemic evaluation in patients with AF.

330	References:				
331	1.	Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of			
332		atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.			
333		Circ Res. 2014;114(9):1453-1468.			
334					
335	2.	Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in			
336		the 21st Century: Novel Methods and New Insights. Circ Res. 2020;127(1):4-20.			
337					
338	3.	Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and			
339		modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20(6):404-417.			
340					
341	4.	Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP,			
342		Chamberlain AM, Chang AR, Cheng S, Delling FN et al. Heart Disease and Stroke			
343		Statistics-2020 Update: A Report From the American Heart Association. Circulation.			
344		2020;141(9):e139-e596.			
345					
346	5.	Deshmukh A, Iglesias M, Khanna R, Beaulieu T. Healthcare utilization and costs			
347		associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2.			

It is made available under a CC-BY-NC-ND 4.0 International license .

348	2022;3(5):577-586.
-----	--------------------

350	6.	Olvera Lopez E, Ballard BD, Jan A. Cardiovascular Disease. In: StatPearls. Treasure
351		Island (FL): StatPearls Publishing; August 22, 2023.
352		
353	7.	Brown JC, Gerhardt TE, Kwon E. Risk Factors for Coronary Artery Disease. In:
354		StatPearls. Treasure Island (FL): StatPearls Publishing; January 23, 2023.
355		
356	8.	Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery
357		Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health.
358		2021;11(2):169-177.
359		
360	9.	GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-
361		specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a
362		systematic analysis for the Global Burden of Disease Study 2017. Lancet.
363		2018;392(10159):1736-1788.
364		
365	10	Murphy MM, Schmier JK. Cardiovascular Healthcare Cost Savings Associated with
366		Increased Whole Grains Consumption among Adults in the United States. Nutrients.
367		2020;12(8):2323.
368		

369	11. Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives. Heart Views.
370	2017;18(3):109-114.
371	
372	12. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J.
373	Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med
374	Sci. 2018;63(1):30-35.
375	
376	13. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL,
377	Judd S, Howard VJ, Howard G et al. Atrial Fibrillation and the Risk of Myocardial
378	Infarction. JAMA Intern Med. 2014;174(1):107–114.
379	
380	14. Yan T, Zhu S, Xie C, Zhu M, Weng F, Wang C, Guo C. Coronary Artery Disease and
381	Atrial Fibrillation: A Bidirectional Mendelian Randomization Study. J Cardiovasc Dev
382	Dis. 2022;9(3):69.
383	
384	15. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, Oldgren J. All types
385	of atrial fibrillation in the setting of myocardial infarction are associated with impaired
386	outcomes. Heart. 2016;102(12):926-933.
387	
388	16. Stojadinović P, Deshraju A, Wichterle D, Fukunaga M, Peichl P, Kautzner J, Sramko M.
389	The hemodynamic effect of simulated atrial fibrillation on left ventricular function. J
390	Cardiovasc Electrophysiol. 2022;33(12):2569-2577.
391	

392	17. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP).
393	2019. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-
394	us.ahrq.gov/nisoverview.jsp
395	
396	18. Sharma YP, Batta A, Makkar K, Hatwal J, Gawalkar AA, Kaur N, Malhi TS,
397	Kasinadhuni G, Gupta H, Panda P, et al. Angiographic profile and outcomes in persistent
398	non-valvular atrial fibrillation: A study from tertiary care center in North India. Indian
399	Heart J. 2022;74(1):7-12.
400	
401	19. Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk Factor Management
402	in Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2018;7(2):118-127.
403	
404	20. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F, Jouven X.
405	Mortality associated with atrial fibrillation in patients with myocardial infarction: a
406	systematic review and meta-analysis. Circulation. 2011;123(15):1587-1593.
407	
408	21. Tsigkas G, Kopsida G, Xanthopoulou I, Davlouros P, Koutsogiannis N, Makris G,
409	Theodoropoulos K, Kassimis G, Gkizas V, Hahalis G, et al. Diagnostic accuracy of
410	electrocardiographic ST-segment depression in patients with rapid atrial fibrillation for
411	the prediction of coronary artery disease. Can J Cardiol. 2014;30(8):920-924.
412	
413	22. Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson Jr
414	FA, Fox KAA, Gore JM, Goldberg RJ, Eagle KA. Comparison of outcomes of patients

415	with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol.
416	2003;92(9):1031-1036.
417	
418	23. Polimeni L, Perri L, Saliola M, Basili S, Violi F. The risk of myocardial infarction in
419	patients with atrial fibrillation: an unresolved issue. Intern Emerg Med. 2010;5(2):91-94.
420	
421	24. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable Risk Factors and Atrial
422	Fibrillation. Circulation. 2017;136(6):583-596.
423	
424	25. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of
425	atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114(9):1483-
426	1499.
427	
428	26. Garg RK, Jolly N. Acute myocardial infarction secondary to thromboembolism in a
429	patient with atrial fibrillation. Int J Cardiol. 2007;123(1):e18-e20.
430	
431	27. Tomcsányi J, Takó K, Sármán B. Recidív akut myocardialis infarctus pitvarfibrilláció
432	miatt [Recurrent acute myocardial infarction as a thromboembolic complication of atrial
433	fibrillation]. Orv Hetil. 2016;157(5):191-193.
434	
435	28. Kea B, Alligood T, Manning V, Raitt M. A Review of the Relationship of Atrial
436	Fibrillation and Acute Coronary Syndrome. Curr Emerg Hosp Med Rep. 2016;4(3):107-

It is made available under a CC-BY-NC-ND 4.0 International license .

437 118. 438 29. Tomaszuk-Kazberuk A, Młodawska E, Łopatowska P, Kaminski M, Michniewicz E, 439 Bachorzewska-Gajewska H, Dobrzycki S, Musial W. Atrial fibrillation as a factor 440 associated with a finding of non-significant coronary disease on coronary angiography -441 difficulties in qualifying for coronary angiography - 15 853 patients study. Eur Heart J. 442 2017;38(suppl_1). 443 444 30. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, 445 446 Themeles E, Ezekowitz M, Wallentin L, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation 447 of long-term anticoagulant therapy study. Circulation. 2013;128(20):2192-2201. 448 449 31. Soliman EZ, Lopez F, O'Neal WT, Chen LY, Bengtson L, Zhang Z, Loehr L, Cushman 450 451 M, Alonso A. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities 452 (ARIC) Study. Circulation. 2015;131(21):1843-1850. 453 454 32. He W, Chu Y. Atrial fibrillation as a prognostic indicator of myocardial infarction and 455 cardiovascular death: a systematic review and meta-analysis. Sci Rep. 2017;7(1):3360. 456 Published 2017 June 13. 457

It is made available under a CC-BY-NC-ND 4.0 International license .

- 459 **33**. Motloch LJ, Reda S, Larbig R, Wolff A, Motloch KA, Wernly B, Granitz C, Lichtenauer
- 460 M, Wolny M, Hoppe UC. Characteristics of coronary artery disease among patients with
- 461 atrial fibrillation compared to patients with sinus rhythm. Hellenic J Cardiol.
- 462 2017;58(3):204-212.

463

- 465 **Tables:**
- 466 Table 1. Patient characteristics

Patient characteristics	AMI with AF	AMI without AF	p-value			
% of patients	1					
Women, %	37%	36%	0.0153			
Age, mean	74 years (0.5)	65 years (0.2)				
Race/ethnicity, %						
Caucasian	80%	72%	_			
African American	7.5%	12%	_			
Hispanic	6.5%	9.2%	0.000			
Asian or Pacific	2.6%	3%				
Islander						
Native American	0.4%	0.6%	—			
Other	2.3%	3.1%	—			
Charlson comorbidity i						

0	0	0	
1	11.6%	26%	0.000
2	19.5%	26%	
>3	69	48%	
Median annual incor	me in patients' z	tip code, %	
\$1 - 45,999	28.6%	31%	
\$46,000 - 58,999	27.2%	26.3%	0.000
\$59,000 - 78,999	25%	24%	
> \$79,000	19.3%	18.3%	
Insurance type, %			
Medicare	77%	54%	
Medicaid	5%	11%	0.000
Private HMO	15%	30%	
Self-pay	2.3%	5.7%	
Hospital characterist	tics		
Hospital region, %			
Northeast	17%	17%	
Midwest	24%	22%	0.000
South	39%	41%	
West	20%	19%	
Hospital bed size, %	[
Small	19%	19%	

It is made available under a CC-BY-NC-ND 4.0 International license .

Medium	30%	30%	0.3233			
Large	51%	50%				
Urban location	93%	93%	0.853			
Hospital teaching	74	74	0.0903			
status						
AMI, Acute myocardial infarction; AF, atrial fibrillation. Actual numbers not provided						
as the sample size was above 10,000						

467

468 Table 2. The difference in mortality between patients with and without AF

	Total	AMI with AF	AMI without AF					
Total AMI no. (%)	26,955/600,645	7860/109,520	19,095/491,125					
	(4.5%)	(7.2%)	(3.9%)					
STEMI no. (%)	13,025/166,680	3165/23,320	9,860/143,360					
	(7.8%)	(13.5%)	(6.8%)					
NSTEMI no. (%)	13,930/433,965	4695/86,200	9,235/347,765					
	(3.2%)	(5.4%)	(2.6%)					
AMI, Acute myocardial infarction; AF, atrial fibrillation; STEMI, ST-elevation								
myocardial infarction;	myocardial infarction; NSTEMI, non-ST elevation myocardial infarction							

It is made available under a CC-BY-NC-ND 4.0 International license .

470 Table 3. Adjusted and unadjusted odds of mortality in patients with AMI, STEMI, and NSTEMI

471 and concomitant AF

	ŀ	AMI	ST	EMI	NSTEMI		
	Unadjusted	Adjusted	Unadjusted	Adjusted	Unadjusted	Adjusted	
Mortality	OR (95%						
	CI)	CI)	CI)	CI)	CI)	CI)	
	1.91 (1.79-	1.23 (1.15-	2.12 (1.93-	1.23 (1.09-	2.11 (1.95-	1.32 (1.21-	
	2.03)	1.32)	2.34)	1.38)	2.28)	1.45)	
AMI, Acute myocardial infarction; AF, atrial fibrillation; STEMI, ST-elevation myocardial							
infarction; NSTEMI, non-ST elevation myocardial infarction							

- 473 Table 4. The unadjusted and adjusted Odds ratios of stress test, diagnostic coronary angiogram,
- and PCI in patients with AMI, STEMI, NSTEMI, and AF.

	AMI		STEMI		NSTEMI	
	Unadjusted OR	Adjusted OR	Unadjusted	Adjusted	Unadjusted	Adjusted
	(95% CI)	(95% CI)	OR (95%	OR (95%	OR (95%	OR (95%
			CI)	CI)	CI)	CI)
Stress test	0.83 (0.61-1.11)	0.70 (0.51-0.96)	1.67 (0.78-	1.51 (0.68-	0.71 (0.51-	0.64 (0.45-
			3.58)	3.32)	0.98)	0.89)
Diagnostic	0.55 (0.53-0.56)	0.77 (0.744-0.80)	0.51 (0.47-	0.75 (0.67-	0.59 (0.57-	0.79 (0.75-

It is made available under a CC-BY-NC-ND 4.0 International license .

coronary			0.56)	0.82)	0.61)	0.82)		
angiogram								
PCI	0.49 (0.47-0.50)	0.64 (0.62-0.67)	0.47 (0.44-	0.65 (0.59-	0.52 (0.50-	0.62 (0.59-		
			0.51)	0.70)	0.54)	0.64)		
AMI, Acute n	AMI, Acute myocardial infarction; AF, atrial fibrillation; STEMI, ST-elevation myocardial infarction;							
NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention								

475

Table 5. Unadjusted and Adjusted Odds ratios for Ventricular tachycardia, Ventricular

477 fibrillation, Cardiogenic shock, and Cardiac arrest in patients with AMI, STEMI, NSTEMI, and

478 AF.

	AMI		STEMI		NSTEMI	
	Unadjusted	Adjusted	Unadjusted	Adjusted	Unadjusted	Adjusted OR
	OR (95% CI)	OR (95%	OR (95%	OR (95%	OR (95%	(95% CI)
		CI)	CI)	CI)	CI)	
Ventricular	1.44 (1.36-	1.41 (1.33-	1.53 (1.41-	1.44 (1.32-	1.68 (1.57-	1.44 (1.33-
tachycardia	1.52)	1.49)	1.66)	1.58)	1.80)	1.56)
Ventricular	1.32 (1.22-	1.44 (1.33-	1.57 (1.43-	1.50 (1.34-	1.74 (1.52-	1.51 (1.30-
fibrillation	1.42)	1.57)	1.73)	1.68)	1.98)	1.76)
Cardiogenic	1.83 (1.73-	1.43 (1.35-	2.31 (2.14-	1.57 (1.43-	2.05 (1.89-	1.46 (1.33-
shock	1.93)	1.52)	2.49)	1.73)	2.22)	1.59)

It is made available under a CC-BY-NC-ND 4.0 International license .

Cardiac arrest	1.52 (1.41-	1.35 (1.24-	1.74 (1.56-	1.50 (1.32-	1.73 (1.54-	1.43 (1.26-		
	1.64)	1.47)	1.94)	1.71)	1.94)	1.63)		
AMI, Acute my	AMI, Acute myocardial infarction; AF, atrial fibrillation; STEMI, ST-elevation myocardial infarction;							
NSTEMI, non-ST elevation myocardial infarction								

479

480 Table 6. Adjusted length of stay and total hospital charges for AMI, STEMI NSTEMI, and AF

	AN	AMI		STEMI		NSTEMI	
	Unadjusted	Adjusted	Unadjusted	Adjusted	Unadjusted	Adjusted	
	OR (95%	OR (95%	OR (95%	OR (95%	OR (95%	OR (95%	
	CI)	CI)	CI)	CI)	CI)	CI)	
LOS	2.23 (2.12-	1.39 (1.29-	2.5 (2.28-	1.49 (1.28-	2.11 (2.00-	1.34 (1.24-	
	2.33)	1.48)	2.72)	1.71)	2.22)	1.44)	
Total	27,632	\$22,188	39,063	\$22,577	27,098	\$20,843	
charges	(24,445-	(19,311-	(33,125-	(16,622-	(23,817-	(17,898-	
	30,818)	25,064)	45,000)	28,532)	30,379)	23,788)	
AMI, Acute myocardial infarction; AF, atrial fibrillation; STEMI, ST-elevation myocardial							

infarction; NSTEMI, non-ST elevation myocardial infarction; LOS, length of stay